Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician

Share:

 
 

Jeff Yorio, M.D.

Jeff Yorio, M.D.

Provider Type: Physician

Specialties:
  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Hematology
  • Internal Medicine

Metro Area: Austin
Clinical Trials in Austin

Downloads

General Summary

Dr. Yorio is a native Texan, born and raised in Burleson near Fort Worth.  He is board certified in medical oncology, hematology, and internal medicine.  He is actively involved in clinical trial research for melanoma, head & neck cancer, renal cell carcinoma and prostate cancer with publications in the areas of melanoma, lung cancer and colorectal cancer. He strives to bring cutting edge treatments and new research to patients here in Austin.

Education

  • Fellowship in Medical Oncology and Hematology
    UT MD Anderson Cancer Center, Houston, TX
  • Residency in Internal Medicine
    UT Southwestern Medical Center, Dallas, TX
  • Doctor of Medicine with Distinction in Research
    The University of Texas Southwestern Medical Center, Dallas, TX
  • Bachelor of Science in Advertising
  • The University of Texas, Austin, TX 

Accolades & Memberships

Affiliations

  • Chief of Hematology-Oncology Service, Seton Medical Center Austin
  • Chair of Oncology Subcommittee, Seton Health Alliance
  • Chair of Marketing Committee, Texas Oncology Austin
  • Executive Committee, Texas Oncology Austin
  • Developmental Therapeutics Research Committee Member, US Oncology
  • Genitourinary Research Committee Member, US Oncology
  • American Society of Clinical Oncology Member
  • American Society of Hematology Member
  • Travis County Medical Society Member
Awards
  • Jesse H. Jones Fellowship in Cancer Education, UT MD Anderson, 2013
  • LBJ Clinical Fellow of the Year, UT MD Anderson, 2013 
  • Educational Grant, National Comprehensive Cancer Network Fellow Recognition Program at the NCCN 18th Annual Conference, 2013
  • Outstanding Clinical Research Award, UT Southwestern Housestaff, 2011
  • Outstanding Clinical Research Award, Eastern Cooperative Oncology Group (ECOG) Young Investigator’s Symposium, 2008
  • National Institute of Health T-35 Training Grant for Medical Student Research, 2005

Research Interest

Dr. Yorio has been actively involved in research since his early days of medical school and training at UT Southwestern where he received a Doctor of Medicine with Distinction in Research and was given the award for Outstanding Clinical Research amongst his peers in residency.  He is currently the Austin Area Physician Team Leader for melanoma and genitourinary cancer research, and has served as a national and local principal investigator for multiple clinical trials for melanoma, head & neck cancer, renal cell carcinoma and prostate cancer.

Other Information

Dr. Yorio and his wife met as undergraduate students at The University of Texas, and like many Longhorns, wanted to make Austin their lifelong home.  He enjoys spending time with his wife and two amazing children, playing guitar, coaching his kid’s basketball teams, jogging, skiing, and paddleboarding.  He and his family are also avid Texas Longhorn fans.

Latest News

Show all News

Publications

  • Phase 3 Study of Pembrolizumab Plus Chemoradiation (CRT) vs CRT Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    Society for Immunotherapy of Cancer (SITC) 2017 Conference, 2017

  • An Interprofessionally Developed Geriatric Oncology Curriculum for Hematology-Oncology Fellows

    Journal of Geriatric Oncology, 2015

  • A Case of Vemurafenib-Induced Sweet’s Syndrome

    The Journal of Dermatology, 2014

  • Treatment Decisions in a Man with Hodgkin Lymphoma and Guillian-Barre Syndrome: A Case Report

    Journal of Medical Case Reports, 2014

  • Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non-Small Cell Lung Cancer

    Clinical Lung Cancer, 2013

Show all Publications
  • Rare Though Not Mutually Exclusive: a Report of Three Cases of Concomitant Kras and Braf Mutation and a Review of the Literature

    Journal of Cancer, 2013

  • Toxicities and Outcomes in Metastatic Melanoma Patients Treated with Ipilimumab and Braf Inhibitors

    Society for Melanoma Research 2013 Congress, 2013

  • Improving the Care of Acute Lymphocytic Leukemia (ALL) at a Large County Hospital

    American Society of Clinical Oncology Quality Care Symposium, 2013

  • Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

    American Society of Clinical Oncology National Meeting, 2013

  • Assessment of Absolute Lymphocyte Count (ALC) as a Predictor of Progression-Free Survival (PFS) and Overall Response Rate (ORR) in Metastatic Melanoma (MM) Patients (PTS) Treated with High-Dose Interleukin-2 (HD Il-2)

    ASCO Annual Meeting, 2013

  • How Have We Diagnosed Early-Stage Lung Cancer Without Radiographic Screening? A Contemporary Single-Center Experience

    PLoS ONE, 2012

  • Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical Center

    Clinical Lung Cancer, 2012

  • Recent Advances and Emerging Therapies in the Systemic Treatment of Metastatic Melanoma

    Clinical Oncology News, 2012

  • A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas

    International Journal of Surgical Oncology, 2012

  • Presentation of Early-Stage Non-Small Cell Lung Cancer (NSCLC) Without Radiographic Screening: End of an Era?

    ASCO Annual Meeting, 2011

  • The Influence of Medical Comorbidities on the Presentation and Outcome of Stage I-III Non-Small Cell Lung Cancer

    2010 ASCO Annual Meeting, 2010

  • The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

    ASCO Annual Meeting, 2009

  • The Association Between Clinical Characteristics, Treatment Modality and Outcomes of Non-Small Cell Lung Cancer

    American Society of Clinical Oncology National Meeting– Orlando, FL, 2009

  • Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity

    Journal of Thoracic Oncology, 2009

  • The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

    Journal of Investigative Medicine, 2008

  • The Association Between Patient Characteristics, Health Care System Characteristics and Clinical Outcomes in Non-Small Cell Lung Cancer

    Eastern Cooperative Oncology Group National Meeting, 2008

  • The Effect of a Disease Management Algorithm and Dedicated Post-ACS Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study

    Sixth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2006

  • Increasing Use of Evidence-Based Therapies Across Ethnic Groups After Acute Coronary Events: Observations from the Parkland Acute Coronary Event Treatment Study

    Fifth Annual University of Texas Southwestern Cardiovascular Symposium – Dallas, TX, 2005